JPH11514843A5 - - Google Patents

Info

Publication number
JPH11514843A5
JPH11514843A5 JP1997500962A JP50096297A JPH11514843A5 JP H11514843 A5 JPH11514843 A5 JP H11514843A5 JP 1997500962 A JP1997500962 A JP 1997500962A JP 50096297 A JP50096297 A JP 50096297A JP H11514843 A5 JPH11514843 A5 JP H11514843A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997500962A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11514843A (ja
Filing date
Publication date
Priority claimed from US08/472,527 external-priority patent/US6040296A/en
Application filed filed Critical
Publication of JPH11514843A publication Critical patent/JPH11514843A/ja
Publication of JPH11514843A5 publication Critical patent/JPH11514843A5/ja
Ceased legal-status Critical Current

Links

JP9500962A 1995-06-07 1996-06-03 喘息の治療方法 Ceased JPH11514843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/472,527 US6040296A (en) 1995-06-07 1995-06-07 Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US08/472,527 1995-06-07
PCT/US1996/008325 WO1996040266A1 (en) 1995-06-07 1996-06-03 Method of treatment for asthma

Publications (2)

Publication Number Publication Date
JPH11514843A JPH11514843A (ja) 1999-12-21
JPH11514843A5 true JPH11514843A5 (enExample) 2004-07-22

Family

ID=23875872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9500962A Ceased JPH11514843A (ja) 1995-06-07 1996-06-03 喘息の治療方法

Country Status (6)

Country Link
US (1) US6040296A (enExample)
EP (1) EP0831924A4 (enExample)
JP (1) JPH11514843A (enExample)
CN (1) CN1192158A (enExample)
CA (1) CA2223769C (enExample)
WO (1) WO1996040266A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153602B1 (en) * 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
KR20010030622A (ko) * 1997-09-17 2001-04-16 리차드 알. 이킨 다중 표적 하이브리드형성 핵산과 그들의 제조, 구성,제제, 키트 및 응용
IL139646A0 (en) * 1998-05-14 2002-02-10 Coley Pharm Group Inc Methods for regulating hematopoiesis using cpg-oligonucleotides
CA2316994A1 (en) * 1998-06-08 1999-12-16 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
WO2000062736A2 (en) * 1999-04-06 2000-10-26 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
AU4036600A (en) * 2000-03-28 2001-10-08 Isis Pharmaceuticals Inc Alteration of cellular behavior by antisense modulation of mrna processing
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
AU2001296846B2 (en) 2000-10-12 2007-07-05 University Of Rochester Compositions that inhibit proliferation of cancer cells
IL159722A0 (en) * 2001-07-10 2004-06-20 Oligos Etc Inc Pharmaceutical compositions containing oligonucleotides
EP1572168B1 (en) 2002-02-06 2010-05-26 Vicor Technologies, Inc. Anti-infarction molecules
EP1534729A2 (en) * 2002-02-26 2005-06-01 University of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
US20050287648A1 (en) 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
AU2003300919A1 (en) * 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
EP1608403A2 (en) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
CA2564868C (en) * 2004-04-28 2013-11-26 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
US7968762B2 (en) * 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
HRP20070516A2 (en) * 2005-04-08 2008-12-31 Coley Pharmaceutical Group Methods for treating infectious disease exacerbated asthma
EP2395076A1 (en) 2005-10-14 2011-12-14 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20100190689A1 (en) 2006-09-21 2010-07-29 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
EP2104509A4 (en) 2006-12-11 2010-03-24 Univ Utah Res Found COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL ANGIOGENESIS AND VASPERMEABILITY
US9526707B2 (en) * 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8501912B2 (en) * 2007-12-03 2013-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Filipil compositions and methods for treating cancer
JP5653899B2 (ja) 2008-03-17 2015-01-14 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 神経筋シナプスの維持および再生に関与するマイクロrnaの同定
EP2288922B1 (en) 2008-05-08 2016-08-17 University of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
WO2010027641A2 (en) * 2008-08-15 2010-03-11 Georgetown University Na channels, disease, and related assays and compositions
EP2350264A4 (en) 2008-11-06 2012-08-29 Univ Johns Hopkins TREATMENT OF CHRONIC INFLAMMATION OF THE RESPIRATORY TRACT
EP2370080A1 (en) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
PL2580243T3 (pl) 2010-06-09 2020-05-18 Genmab A/S Przeciwciała przeciwko ludzkiemu CD38
JP5598510B2 (ja) 2012-08-28 2014-10-01 トヨタ自動車株式会社 内燃機関
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
CN105960410B (zh) 2013-11-21 2020-12-04 硒瑞恩生物科技有限公司 硒衍生的核酸复合物的结构测定方法
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
DK3491014T5 (da) 2016-07-28 2024-09-02 Regeneron Pharma Allel-specifik primer eller sonde, som er hybridiseret til et nucleinsyremolekyle, som koder for en GPR156 variant
MX2019001364A (es) 2016-08-03 2019-08-01 H Lee Moffitt Cancer Ct & Res Agentes terapeuticos orientados a tlr9.
CN110446785B (zh) 2017-01-23 2024-04-26 瑞泽恩制药公司 Hsd17b13变体及其应用
KR102624979B1 (ko) 2017-06-05 2024-01-16 리제너론 파마슈티칼스 인코포레이티드 B4galt1 변이체 및 이의 용도
EP3679158B1 (en) 2017-09-06 2025-04-30 Regeneron Pharmaceuticals, Inc. Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
RU2020112313A (ru) 2017-09-07 2021-10-08 Ридженерон Фармасьютикалз, Инк. Варианты члена 1 семейства 14 переносчиков растворенных веществ (slc14a1)и их применение
US12016314B2 (en) 2017-09-08 2024-06-25 Ohio State Innovation Foundation MicroRNA inhibitor therapy in systemic lupus erythematosus
US10961583B2 (en) 2017-10-11 2021-03-30 Regeneron Phramaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
AU2018352234A1 (en) 2017-10-16 2020-04-23 Regeneron Pharmaceuticals, Inc. Cornulin (CRNN) variants and uses thereof
WO2021003295A1 (en) 2019-07-02 2021-01-07 Regeneron Pharmaceuticals, Inc. Modulators of hsd17b13 and methods of use thereof
WO2024173343A1 (en) 2023-02-14 2024-08-22 Regeneron Pharmaceuticals, Inc. Compounds targeting hydroxysteroid 17-beta dehydrogenase (hsd17b) and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5245022A (en) * 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
GB2264948B (en) * 1992-03-13 1996-10-16 Merck & Co Inc Human adenosine receptors
JPH08500967A (ja) * 1992-06-12 1996-02-06 ガーヴァン インスティチュート オブ メディカル リサーチ ヒトA1,A2aおよびA2bアデノシン受容体をエンコードするDNA配列
US5320962A (en) * 1992-07-22 1994-06-14 Duke University DNA encoding the human A1 adenosine receptor
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease

Similar Documents

Publication Publication Date Title
JP2000500228A5 (enExample)
JP2000500445A5 (enExample)
JP2000500440A5 (enExample)
JP2000500327A5 (enExample)
JPH11510742A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500406A5 (enExample)
JP2002515856A5 (enExample)
JP2000500361A5 (enExample)
JPH10510462A5 (enExample)
JPH11514843A5 (enExample)
JP2000500115A5 (enExample)
JP2000500322A5 (enExample)
JPH11512494A5 (enExample)
JP2000500258A5 (enExample)
JP2000500342A5 (enExample)
JP2000500192A5 (enExample)
JPH11507352A5 (enExample)
JP2000500112A5 (enExample)
JP2000500226A5 (enExample)
JPH11507218A5 (enExample)
JP2000500407A5 (enExample)
JP2000500397A5 (enExample)
JP2002515968A5 (enExample)